Latest News and Press Releases

Ad-hoc-Mitteilung gemäss Art. 53 LR Am 23. September 2025 um 14:00 Uhr MESZ / 13:00 Uhr BST / 08:00 Uhr EDT findet eine Telefonkonferenz statt. Einzelheiten finden Sie am Ende dieser...

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln,...

Ad hoc-Mitteilung gemäss Art. 53 KR  Highlights: Santhera sichert sich zusätzliche Finanzmittel in Höhe von rund 20 Millionen CHF von den bestehenden Investoren Highbridge und R-Bridge, um die...

Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global...

Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne muscular dystrophy in Brazil.MILAN, Italy, September 16,...

Entrada Therapeutics announces the recipients of its third annual DREAMS Grant Program.

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0...

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of...

Entrada Therapeutics reports financial results for the second quarter ended June 30, 2025, and highlights recent business updates.

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term...